clinical trial · NCT07425392
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
Pneumococcal Vaccines31-valent pneumococcal conjugate vaccinePCV20
brief summary
The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.
started
Feb 9, 2026
primary completion
Mar 1, 2027
completion
Mar 1, 2027
last updated
Jun 30, 2026
official title
A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Prior Pneumococcal Vaccination
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol